On March 9th, the launch ceremony of Academician Wang Yutian's New Medicine R&D Project was held in Building 12 of Qingdao International Academician Park. Party Committee Secretary Wang Xijing of Licang District, Party Committee Deputy Secretary of Licang District, District Chief Li Xingwei, People's Congress Standing Committee Director of Licang District Guan Xihui, Political Consultative Conference Vice Chairman of Licang District Li Lei, and other leaders attended the event. Academician Wang Yutian’s New Drug R&D project is expected to play a significant role in three major neurological diseases, namely drug addiction, Alzheimer's disease, and cerebrovascular accidents (CVA). It will enjoy broad market prospects and commercial value, and bestow substantial social effects.

Academician Wang Yutian’s team adheres to the philosophy of "serving and helping humanity through scientific research", and focuses on the research and development of Class I innovative patented medicine. At present, research is being conducted on internationally patented peptide based drugs at Qingdao International Academician Park, including pre-clinical and clinical research and development of the Tat-GluA2-3Y polypeptide for treating neurological diseases. Results of the research on the Tat-GluA2-3Y polypeptide show that it has a significant effect on three major neurological diseases, namely drug addiction, Alzheimer's disease, and CVA. These research results have been published in internationally renowned academic journals and have received widespread interest and recognition from international peers. The efficacy of the Tat-GluA2-3Y polypeptide in treating neurological diseases has been validated via independent research results published by several laboratories across the world.

Based in Qingdao International Academician Park, Academician Wang Yutian has a robust, knowledge-driven and talented team that constantly enhances its self-innovation capability. Most of the team members have an overseas educational background and work experience;the core members have world-leading scientific research ability and rich experience in clinical medicine and pharmaceutical enterprise management. Going forward, the team will comprehensively launch the preclinical development of this polypeptide drug, including research on its pharmacodynamics, pharmacokinetics, and toxicology. The team plans to submit the new drugs to CFDA and FDA within three years, obtain clinical approvals for new drugs and apply for multi-center human clinical trials.

Since Qingdao International Academician Park opened in June 2016, nearly 80 Chinese and international academicians have visited the Park to conduct investigations and exchanges. A total of 21 academicians, including Yuan Longping, the “Father of Hybrid Rice" and Academician of Chinese Academy of Engineering, Zhou Shouhuan, the Academician of Chinese Academy of Engineering, Wang Yutian, Fellow of The Royal Society of Canada (the Academy of Sciences of Canada), and Soronen Yuri, Academician of the National Academy of Sciences of Ukraine, have signed on and are conducting research in the Park. Academician Yuan Longping's sea rice R&D project will initiate sea rice breeding in April and transplant the rice in May this year. Academician Zhou Shouhuan's laser application technology project has already generated sales revenues from its main products. The establishment of Qingdao International Academician Park has been highly appreciated by Shandong Provincial and Municipal Party Committees and Municipal Government, and has created a name for itself in the society.